Bjørn Moum | ECCO 2019 | MAALISKUU 11, 2019
In this Norwegian study Bjoern Moum and colleagues aimed to investigate the drug survival of biologics in a national cohort of patients with Crohn’s disease. Data were collected from the Norwegian Patient Registry (NPR) and the Norwegian Prescription Database.
In total, 2444 CD patients were included in the study. After 3 years, the survival rate of first-line biologics for CD patients was 50.3% for infliximab and 40.5% for adalimumab (p < 0.001).
For second-line treatment, the survival rates were 42.4% for infliximab, 42.8% for adalimumab and 69.8% for vedolizumab. Vedolizumab survival was significantly different compared with adalimumab and infliximab (p < 0.001).